Medigus - ADR Free Issuance Announcement

OMER, Israel, June 24, 2015 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced that BNY Mellon’s Depositary Receipts Division is offering free issuances for conversions of Medigus’ ordinary shares into Medigus’ American Depositary Receipts (ADRs) (NASDAQ: MDGS) and will waive the issuance fee for the period 1 June 2015 to the 31 August 2015 inclusive. Please contact the individual listed below to complete your transaction, as this will need to be verified in advance for operational purposes. The Bank of New York Mellon is serving as depositary for Medigus. Each ADR of Medigus represents 100 ordinary shares of Medigus Ltd.

For additional information, please visit BNY Mellon’s website at www.adrbny.com or contact:
Arlene C. Villareal
Phone: 1 212-815-8162
Email: arlene.villareal@bnymellon.com

Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks including possible loss of principal amount invested. This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon provides no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.